The "Checkpoint Inhibitor Refractory Cancer Drugs Market -- Growth, Share, Opportunities & Competitive Analysis, 2025 -- 2032" report has been added to the Credence Research Inc. offering. The global ...

AIM also intends to pursue Japanese Orphan Drug Designation for Ampligen in treatment of pancreatic cancerOCALA, Fla., March 18, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM ...

New research has uncovered immune changes in cancer patients that could help identify which patients are most at risk of dangerous heart complications from cancer drugs, known as immune checkpoint ...

ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical synergy with Topoisomerase 1 ...

Dr. Brian S. Henick, a medical oncologist at Columbia University Irving Medical Center and director of the phase 1 program and translational research in aerodigestive cancers, outlined in an interview ...

Tyrosine kinase inhibitors (TKIs) are metabolized via the cytochrome P450 pathway, which may be associated with the production of toxic intermediates. These drugs can also induce oxidative stress and ...

AIM ImmunoTech (AIM) stock jumped 97% after Japan's Patent Office approved its Ampligen cancer treatment patent covering multiple cancer types through 2039.

UPPSALA, SE / ACCESS Newswire / March 18, 2026 /Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a leader in blood-based biomarkers for cancer treatment monitoring, today ...

New research has uncovered immune changes in cancer patients that could help identify which patients are most at risk of dangerous heart complications from cancer drugs, known as immune checkpoint ...

It's well-known that a person's immune system wears down over time, becoming less effective as folks progress through middle age and become seniors. But that doesn't appear to hinder the effectiveness ...

Most new cancer diagnoses occur in people 65 and older, and overall these folks have worse cancer treatment outcomes, researchers said in background notes. Adobe stock/HealthDay It's well-known that a ...